CD274 and non-small cell lung carcinoma: It remains unknown whether these results are limited to the first‐line use of Pemb‐Plt‐PEM or if the combination of a cytotoxic drug plus Pemb should be considered separately from Pemb in individuals with NSCLC and high PD‐L1 expression levels.